文献速递儿科与产科急症心脑血管急症重症综合管理与镇静镇痛

58例儿童SARS-CoV-2相关儿童多系统炎症综合征的临床特征

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
PubMed 文献 · JAMA · 2020-01-01
一句话结论58例PIMS-TS患儿中78%有现症或既往SARS-CoV-2感染证据,29例出现休克需正性肌力支持,8例(14%)发生冠状动脉扩张或动脉瘤。

该病例系列纳入英格兰8家医院2020年3月23日至5月16日收治的58例符合PIMS-TS定义的持续发热伴炎症证据患儿,中位年龄9岁,78%有现症或既往SARS-CoV-2感染证据。所有患儿均有发热和非特异性症状,炎症标志物显著升高(CRP中位229 mg/L)。29例出现休克伴心肌功能障碍生物化学证据并需正性肌力支持及液体复苏,其中23例(79%)接受机械通气;8例(14%)发生冠状动脉扩张或动脉瘤。与川崎病及川崎病休克综合征相比,PIMS-TS患儿年龄更大且炎症标志物升高更明显,提示该综合征不同于其他儿童炎症性疾病。

要点

  • 58例PIMS-TS患儿中45例(78%)有现症或既往SARS-CoV-2感染证据,SARS-CoV-2 IgG阳性40/46(87%)。
  • 29/58例出现休克伴心肌功能障碍生物化学证据,需正性肌力支持及液体复苏,其中23/29(79%)接受机械通气。
  • 8/58例(14%)发生冠状动脉扩张或动脉瘤;13例符合美国心脏协会川崎病定义。
  • 所有患儿均有发热,常见胃肠道症状:呕吐26/58(45%)、腹痛31/58(53%)、腹泻30/58(52%);皮疹30/58(52%)、结膜充血26/58(45%)。
  • 与川崎病及川崎病休克综合征相比,PIMS-TS患儿年龄更大(中位9岁 vs 2.7岁 vs 3.8岁),CRP升高更明显(229 mg/L vs 67 mg/L vs 193 mg/L)。

适用人群与场景

  • 英格兰8家医院2020年3月23日至5月16日收治的持续发热伴实验室炎症证据、符合PIMS-TS发表定义的58例儿童(中位年龄9岁,IQR 5.7-14;女童20例,34%)。

诊断标准与关键阈值

  • 符合英国、美国及世界卫生组织发布的PIMS-TS定义标准。
  • 美国心脏协会川崎病定义:13/58例符合。

处置流程与药物剂量

  • 29例出现休克伴心肌功能障碍生物化学证据,接受正性肌力支持及液体复苏,其中23/29(79%)接受机械通气。

红旗征与不能漏的情况

  • 29/58例出现休克伴心肌功能障碍生物化学证据,需正性肌力支持及液体复苏。
  • 8/58例(14%)发生冠状动脉扩张或动脉瘤。

研究设计与关键结果

  • 病例系列:英格兰8家医院58例PIMS-TS患儿,中位年龄9岁(IQR 5.7-14),20例女童(34%)。
  • SARS-CoV-2 PCR阳性15/58(26%),SARS-CoV-2 IgG阳性40/46(87%),45/58(78%)有现症或既往SARS-CoV-2感染证据。
  • 所有患儿均有发热及非特异性症状:呕吐26/58(45%)、腹痛31/58(53%)、腹泻30/58(52%)、皮疹30/58(52%)、结膜充血26/58(45%)。
  • CRP中位229 mg/L(IQR 156-338,58/58评估),铁蛋白中位610 μg/L(IQR 359-1280,53/58评估)。
  • 29例出现休克伴心肌功能障碍生物化学证据,需正性肌力支持及液体复苏,其中23/29(79%)接受机械通气;13例符合美国心脏协会川崎病定义;23例有发热和炎症但无休克或川崎病特征。
  • 8例(14%)发生冠状动脉扩张或动脉瘤。
  • 与川崎病(n=1132)及川崎病休克综合征(n=45)比较:PIMS-TS年龄更大(中位9岁[IQR 5.7-14] vs 2.7岁[IQR 1.4-4.7] vs 3.8岁[IQR 0.2-18]);CRP更高(中位229 mg/L[IQR 156-338] vs 67 mg/L[IQR 40-150] vs 193 mg/L[IQR 83-237])。

证据类型、等级与局限

  • 证据类型:病例系列(58例,来自8家医院)。
  • 比较对象为2002至2019年欧洲和美国医院收治的川崎病(n=1132)、川崎病休克综合征(n=45)及中毒性休克综合征(n=37)患者的临床特征。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与川崎病及川崎病休克综合征患者的比较为认识该综合征提供了线索,并提示该疾病不同于其他儿童炎症性疾病。
  • 作者指出,该病例系列中PIMS-TS患儿表现谱广泛、疾病严重程度不一,从发热和炎症到心肌损伤、休克及冠状动脉瘤形成。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.

OBJECTIVES: To describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.

DESIGN, SETTING, AND PARTICIPANTS: Case series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n = 45), and toxic shock syndrome (n = 37) who had been admitted to hospitals in Europe and the US from 2002 to 2019.

EXPOSURES: Signs and symptoms and laboratory and imaging findings of children who met definitional criteria for PIMS-TS from the UK, the US, and World Health Organization.

MAIN OUTCOMES AND MEASURES: Clinical, laboratory, and imaging characteristics of children meeting definitional criteria for PIMS-TS, and comparison with the characteristics of other pediatric inflammatory disorders.

RESULTS: Fifty-eight children (median age, 9 years [interquartile range {IQR}, 5.7-14]; 20 girls [34%]) were identified who met the criteria for PIMS-TS. Results from SARS-CoV-2 polymerase chain reaction tests were positive in 15 of 58 patients (26%) and SARS-CoV-2 IgG test results were positive in 40 of 46 (87%). In total, 45 of 58 patients (78%) had evidence of current or prior SARS-CoV-2 infection. All children presented with fever and nonspecific symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), and diarrhea (30/58 [52%]). Rash was present in 30 of 58 (52%), and conjunctival injection in 26 of 58 (45%) cases. Laboratory evaluation was consistent with marked inflammation, for example, C-reactive protein (229 mg/L [IQR, 156-338], assessed in 58 of 58) and ferritin (610 μg/L [IQR, 359-1280], assessed in 53 of 58). Of the 58 children, 29 developed shock (with biochemical evidence of myocardial dysfunction) and required inotropic support and fluid resuscitation (including 23/29 [79%] who received mechanical ventilation); 13 met the American Heart Association definition of KD, and 23 had fever and inflammation without features of shock or KD. Eight patients (14%) developed coronary artery dilatation or aneurysm. Comparison of PIMS-TS with KD and with KD shock syndrome showed differences in clinical and laboratory features, including older age (median age, 9 years [IQR, 5.7-14] vs 2.7 years [IQR, 1.4-4.7] and 3.8 years [IQR, 0.2-18], respectively), and greater elevation of inflammatory markers such as C-reactive protein (median, 229 mg/L [IQR 156-338] vs 67 mg/L [IQR, 40-150 mg/L] and 193 mg/L [IQR, 83-237], respectively).

CONCLUSIONS AND RELEVANCE: In this case series of hospitalized children who met criteria for PIMS-TS, there was a wide spectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock, and development of coronary artery aneurysms. The comparison with patients with KD and KD shock syndrome provides insights into this syndrome, and suggests this disorder differs from other pediatric inflammatory entities.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020. PMID: 32511692. doi:10.1001/jama.2020.10369

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。